Innate Pharma S.A.'s filings document the company's foreign private issuer reporting, oncology pipeline disclosures, governance matters, and share-capital information. Form 6-K reports furnish company press releases covering clinical-stage immunotherapy programs, business updates, investor and scientific conference activity, Annual General Meeting materials, and French share and voting-right notifications.
The company's Form 20-F annual report and Universal Registration Document address annual financial reporting, management discussion, corporate governance, statutory auditor reports, and risk factors for a biotechnology issuer developing antibody therapeutics. Filings also reference registration statements on Form F-3 and Form S-8 and disclose Nasdaq and Euronext Paris trading identifiers.
Innate Pharma S.A. filed a Form 6-K to share details of an upcoming conference call and webcast for its full year 2025 financial results. The call will take place on Thursday, March 26, 2026 at 2 p.m. CET / 9 a.m. EDT, following the release of results for the year ended December 31, 2025.
Senior leadership, including the Chief Executive Officer, Chief Medical Officer, Chief Operating Officer, Chief Financial Officer and Vice President of Investor Relations, will participate. The event will be accessible via webcast and telephone, with a replay available on the company’s website for 90 days.
Innate Pharma SA ownership update: Novo Nordisk A/S reports beneficial ownership of 7,333,778 ordinary shares, representing 7.82% of the class as of 12/31/2025. The filing shows sole voting and dispositive power over 7,333,778 shares.
The form is an amended Schedule 13G/A filed and signed on 03/04/2026 by Karsten Munk Knudsen, Chief Financial Officer.
Innate Pharma S.A. filed a report noting that its executive team will take part in the Leerink Partners Global Healthcare Conference 2026 in Miami from March 8–11. The company will host a fireside chat on March 9 at 3:40 PM ET, with a live webcast and replay available through the Investors section of its website.
The filing also highlights Innate Pharma’s focus on developing next-generation antibody-based immunotherapies for cancer, including IPH4502, lacutamab and monalizumab, and mentions ongoing collaborations with major partners such as AstraZeneca and Sanofi.
Innate Pharma SA filed an amended ownership report showing that AstraZeneca PLC and its wholly owned subsidiary MedImmune Limited together beneficially own 7,825,501 Ordinary Shares, including 1,565,001 shares represented by ADSs. This stake represents 8.3% of Innate Pharma’s Ordinary Shares, based on 93,719,323 shares outstanding as of December 31, 2025, as disclosed in a recent Form 6-K. AstraZeneca PLC and MedImmune Limited are each deemed to have sole voting and dispositive power over all shares held by MedImmune Limited, and neither the reporting entities nor their listed directors and officers have traded Innate Pharma shares in the past 60 days.
Innate Pharma S.A. reports its capital and voting structure as of December 31, 2025. The Company had 93,719,323 ordinary shares outstanding, along with 6,324 Preferred Shares 2016 and 7,581 Preferred Shares 2017. Based on French market rules, Innate calculates a total of 94,484,443 theoretical voting rights, which includes all shares with attached voting rights, even those suspended, and incorporates voting rights from AGAP 2016. The number of exercisable voting rights, which excludes treasury shares with suspended rights, was 94,465,868. The Company also highlights its focus on developing next-generation immunotherapies for cancer and notes collaborations with major partners such as AstraZeneca and Sanofi.